Encouraging results were also seen when combining ivosidenib with azacytidine in patients with newly diagnosed IDH1-mutated AML ineligible for intensive chemotherapy in the phase-III AGILE trial. This evidence concerns the gene IDH1 and acute myeloid leukemia.